Clinical Trial

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-06-03
notable Enrollment increased: 387 -> 665 participants 2026-06-03
minor Trial arms changed: 14 -> 20 2026-06-03
notable Trial sites expanded: 11 -> 17 locations 2026-06-03
Trial Details
NCT Number NCT06917079
Lead Sponsor TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Conditions Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C +6 more
Enrollment 665 participants
Start Date 2025-03-31
Primary Completion 2027-08 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-02